- Home
- RPRX
RPRX
Royalty Pharma plc
as 12-24-2024 1:42pm EST
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 11.7B | IPO Year: | 2020 |
| Target Price: | $41.67 | AVG Volume (30 days): | 3.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 2.55 | EPS Growth: | 518.56 |
| 52 Week Low/High: | $24.05 - $31.66 | Next Earning Date: | 02-13-2025 |
| Revenue: | $2,266,003,000 | Revenue Growth: | -2.51% |
| Revenue Growth (this year): | 12.21% | Revenue Growth (next year): | 11.13% |
Latest Royalty Pharma plc News
RPRX Breaking Stock News: Dive into RPRX Ticker-Specific Updates for Smart Investing
Simply Wall St.
8 hours ago
Royalty Pharma plc (NASDAQ:RPRX) is favoured by institutional owners who hold 72% of the company
Insider Monkey
9 hours ago
Jim Cramer Calls Royalty Pharma (RPRX) ‘Disappointing’ But Recommends Holding – ‘I Want You To Stick With It’
GlobeNewswire
a month ago
Royalty Pharma to Present at Upcoming Investor Conferences
Insider Monkey
a month ago
Why Royalty Pharma (RPRX) is the Cheapest Stock to Buy on Robinhood?
GlobeNewswire
a month ago
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare
Simply Wall St.
a month ago
Royalty Pharma's (NASDAQ:RPRX) Profits May Not Reveal Underlying Issues
GlobeNewswire
2 months ago
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
GuruFocus.com
2 months ago
Royalty Pharma PLC (RPRX) Q3 2024 Earnings Call Highlights: Strong Growth and Strategic Acquisitions
Compare RPRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RPRX Royalty Pharma plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.